FDA Approves Lenvima (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma

WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news